| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anticarcinogenic Agents | 20 | 2013 | 371 | 3.130 |
Why?
|
| Mammary Neoplasms, Experimental | 17 | 2011 | 557 | 2.420 |
Why?
|
| Transcription Factor AP-1 | 21 | 2008 | 254 | 2.210 |
Why?
|
| Tetrahydronaphthalenes | 10 | 2011 | 114 | 2.020 |
Why?
|
| Breast Neoplasms | 59 | 2015 | 16186 | 1.780 |
Why?
|
| Receptors, Estrogen | 21 | 2015 | 2264 | 1.650 |
Why?
|
| Aromatase Inhibitors | 8 | 2014 | 314 | 1.310 |
Why?
|
| Selective Estrogen Receptor Modulators | 9 | 2011 | 160 | 1.260 |
Why?
|
| Tamoxifen | 15 | 2014 | 907 | 1.190 |
Why?
|
| Proto-Oncogene Proteins c-jun | 22 | 2008 | 178 | 1.130 |
Why?
|
| Receptors, Retinoic Acid | 8 | 2005 | 374 | 1.060 |
Why?
|
| Retinoids | 12 | 2011 | 151 | 1.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 10 | 2014 | 853 | 1.030 |
Why?
|
| Estrogen Receptor Modulators | 7 | 2011 | 117 | 1.030 |
Why?
|
| Chemoprevention | 8 | 2012 | 251 | 0.990 |
Why?
|
| Raloxifene Hydrochloride | 6 | 2011 | 51 | 0.760 |
Why?
|
| Genes, erbB-2 | 5 | 2008 | 228 | 0.760 |
Why?
|
| Breast | 7 | 2007 | 1364 | 0.740 |
Why?
|
| Quinazolines | 4 | 2009 | 953 | 0.700 |
Why?
|
| Cell Division | 9 | 2015 | 2716 | 0.630 |
Why?
|
| ErbB Receptors | 5 | 2011 | 2379 | 0.610 |
Why?
|
| Mice, Transgenic | 18 | 2011 | 4371 | 0.600 |
Why?
|
| Estrogens | 7 | 2007 | 845 | 0.590 |
Why?
|
| Estrogen Receptor alpha | 6 | 2014 | 744 | 0.580 |
Why?
|
| Mammary Tumor Virus, Mouse | 5 | 2008 | 148 | 0.580 |
Why?
|
| Mammary Glands, Animal | 5 | 2011 | 635 | 0.560 |
Why?
|
| Drug Delivery Systems | 3 | 2010 | 662 | 0.560 |
Why?
|
| Death-Associated Protein Kinases | 1 | 2015 | 22 | 0.510 |
Why?
|
| Precancerous Conditions | 6 | 2009 | 1066 | 0.510 |
Why?
|
| Triazoles | 5 | 2014 | 631 | 0.460 |
Why?
|
| Cell Proliferation | 10 | 2015 | 7294 | 0.460 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2015 | 209 | 0.450 |
Why?
|
| Nitriles | 5 | 2014 | 943 | 0.440 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2015 | 3657 | 0.430 |
Why?
|
| Receptor, ErbB-2 | 4 | 2011 | 2648 | 0.430 |
Why?
|
| Genes, p53 | 2 | 2015 | 1133 | 0.420 |
Why?
|
| Growth Inhibitors | 3 | 2002 | 164 | 0.410 |
Why?
|
| Neoplasms, Hormone-Dependent | 4 | 2009 | 354 | 0.400 |
Why?
|
| Pyrazoles | 3 | 2013 | 1542 | 0.400 |
Why?
|
| Cyclins | 5 | 2008 | 470 | 0.400 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2011 | 2490 | 0.390 |
Why?
|
| Cyclin D1 | 4 | 2009 | 589 | 0.390 |
Why?
|
| Sulfonamides | 3 | 2013 | 1919 | 0.390 |
Why?
|
| Signal Transduction | 16 | 2015 | 12205 | 0.380 |
Why?
|
| Nicotinic Acids | 2 | 2007 | 35 | 0.370 |
Why?
|
| Drug Design | 2 | 2010 | 378 | 0.370 |
Why?
|
| Clinical Trials as Topic | 9 | 2011 | 3862 | 0.360 |
Why?
|
| Female | 66 | 2015 | 148467 | 0.360 |
Why?
|
| Mice | 35 | 2015 | 35990 | 0.360 |
Why?
|
| Neoplasms | 11 | 2015 | 15849 | 0.360 |
Why?
|
| E2F Transcription Factors | 2 | 2007 | 138 | 0.350 |
Why?
|
| Rotenone | 1 | 2009 | 38 | 0.350 |
Why?
|
| Doxycycline | 2 | 2008 | 178 | 0.340 |
Why?
|
| Tretinoin | 4 | 2000 | 621 | 0.330 |
Why?
|
| Disease Models, Animal | 8 | 2012 | 7461 | 0.330 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 5 | 2013 | 203 | 0.330 |
Why?
|
| Calcium Compounds | 1 | 2008 | 8 | 0.330 |
Why?
|
| Cell Transformation, Neoplastic | 7 | 2011 | 2471 | 0.320 |
Why?
|
| Stem Cells | 1 | 2015 | 1230 | 0.320 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2013 | 2670 | 0.320 |
Why?
|
| Mitogen-Activated Protein Kinases | 4 | 2003 | 686 | 0.310 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2009 | 349 | 0.310 |
Why?
|
| Animals | 40 | 2015 | 62759 | 0.300 |
Why?
|
| Antineoplastic Agents | 11 | 2012 | 14678 | 0.300 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2014 | 5435 | 0.300 |
Why?
|
| Humans | 85 | 2015 | 270856 | 0.290 |
Why?
|
| Cell Line, Tumor | 15 | 2015 | 14864 | 0.290 |
Why?
|
| Oncogenes | 3 | 2005 | 700 | 0.290 |
Why?
|
| G1 Phase | 3 | 2005 | 306 | 0.290 |
Why?
|
| Vitamin A | 1 | 2007 | 91 | 0.280 |
Why?
|
| Cell Cycle | 5 | 2009 | 2151 | 0.280 |
Why?
|
| Vitamin D | 1 | 2008 | 261 | 0.270 |
Why?
|
| Retinoid X Receptors | 5 | 2008 | 89 | 0.260 |
Why?
|
| Gene Expression Regulation | 8 | 2011 | 4182 | 0.260 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2004 | 323 | 0.260 |
Why?
|
| Transforming Growth Factor beta | 3 | 2012 | 1132 | 0.260 |
Why?
|
| Mutation | 10 | 2015 | 15841 | 0.260 |
Why?
|
| Preventive Medicine | 1 | 2005 | 32 | 0.250 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2011 | 9078 | 0.250 |
Why?
|
| Drug Evaluation, Preclinical | 5 | 2008 | 504 | 0.250 |
Why?
|
| RNA, Messenger | 10 | 2015 | 6483 | 0.240 |
Why?
|
| Peptide Fragments | 6 | 2008 | 1328 | 0.240 |
Why?
|
| DNA, Neoplasm | 5 | 2007 | 1961 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-fos | 9 | 2005 | 134 | 0.240 |
Why?
|
| Patient Care Management | 1 | 2005 | 94 | 0.240 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2014 | 1347 | 0.230 |
Why?
|
| Transcription Factors | 7 | 2004 | 5494 | 0.230 |
Why?
|
| Biomedical Research | 3 | 2009 | 802 | 0.230 |
Why?
|
| Tetradecanoylphorbol Acetate | 6 | 2004 | 252 | 0.210 |
Why?
|
| Drugs, Investigational | 1 | 2003 | 130 | 0.200 |
Why?
|
| Transcriptional Activation | 8 | 2001 | 1147 | 0.200 |
Why?
|
| Genes, Dominant | 3 | 2004 | 351 | 0.190 |
Why?
|
| Carcinoma | 2 | 2012 | 2627 | 0.190 |
Why?
|
| Insulin-Like Growth Factor I | 4 | 2011 | 649 | 0.180 |
Why?
|
| Estrogen Antagonists | 3 | 2000 | 219 | 0.180 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 6 | 2006 | 308 | 0.180 |
Why?
|
| Celecoxib | 3 | 2013 | 203 | 0.180 |
Why?
|
| Blotting, Western | 7 | 2010 | 3648 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 15 | 2010 | 5834 | 0.170 |
Why?
|
| Muscle Proteins | 1 | 2003 | 557 | 0.170 |
Why?
|
| Models, Biological | 6 | 2011 | 3225 | 0.170 |
Why?
|
| Postmenopause | 2 | 2014 | 380 | 0.170 |
Why?
|
| Enzyme Inhibitors | 2 | 2003 | 1984 | 0.170 |
Why?
|
| Epidermal Growth Factor | 3 | 2009 | 445 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2012 | 546 | 0.160 |
Why?
|
| Risk Assessment | 8 | 2013 | 6832 | 0.160 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2009 | 4956 | 0.160 |
Why?
|
| Cell Growth Processes | 3 | 2009 | 339 | 0.160 |
Why?
|
| Tocopherols | 4 | 2014 | 20 | 0.150 |
Why?
|
| Gene Expression | 5 | 2015 | 3680 | 0.150 |
Why?
|
| Genes, jun | 5 | 2002 | 42 | 0.150 |
Why?
|
| Incidence | 4 | 2009 | 5840 | 0.140 |
Why?
|
| Biomarkers, Tumor | 8 | 2011 | 10698 | 0.140 |
Why?
|
| Transfection | 7 | 2009 | 3169 | 0.140 |
Why?
|
| RNA, Small Interfering | 2 | 2015 | 2214 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2015 | 3920 | 0.140 |
Why?
|
| Gene Expression Profiling | 6 | 2011 | 5161 | 0.130 |
Why?
|
| Transgenes | 3 | 2011 | 589 | 0.130 |
Why?
|
| Drug Administration Schedule | 3 | 2008 | 3540 | 0.130 |
Why?
|
| Mice, Nude | 5 | 2015 | 4360 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2008 | 16593 | 0.120 |
Why?
|
| Cell Line | 8 | 2003 | 5435 | 0.120 |
Why?
|
| Vitamin E | 3 | 2002 | 131 | 0.120 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2007 | 512 | 0.120 |
Why?
|
| Periodicals as Topic | 2 | 2008 | 324 | 0.120 |
Why?
|
| Epithelial Cells | 3 | 2011 | 1887 | 0.120 |
Why?
|
| Cell Differentiation | 8 | 2005 | 4190 | 0.120 |
Why?
|
| Selenium | 1 | 2014 | 51 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 4 | 2009 | 2474 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 2 | 2015 | 2399 | 0.120 |
Why?
|
| Lymphocyte Activation | 5 | 1986 | 1733 | 0.120 |
Why?
|
| Smoking | 3 | 2013 | 2425 | 0.120 |
Why?
|
| Leukotriene E4 | 1 | 2013 | 2 | 0.110 |
Why?
|
| Phosphorylation | 7 | 2014 | 4985 | 0.110 |
Why?
|
| Cadherins | 2 | 2010 | 676 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2001 | 1885 | 0.110 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2013 | 25 | 0.110 |
Why?
|
| Endoplasmic Reticulum | 1 | 2015 | 335 | 0.110 |
Why?
|
| Ki-67 Antigen | 2 | 2007 | 685 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2014 | 5411 | 0.110 |
Why?
|
| Forecasting | 2 | 2006 | 707 | 0.110 |
Why?
|
| Prostaglandins | 1 | 2013 | 83 | 0.110 |
Why?
|
| Progesterone | 2 | 2007 | 731 | 0.110 |
Why?
|
| Genes, fos | 4 | 1999 | 58 | 0.110 |
Why?
|
| Transcription, Genetic | 7 | 2007 | 3415 | 0.100 |
Why?
|
| RNA, Neoplasm | 1 | 2015 | 811 | 0.100 |
Why?
|
| Catechin | 1 | 2012 | 33 | 0.100 |
Why?
|
| Estradiol | 3 | 2014 | 885 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 1084 | 0.100 |
Why?
|
| Hydroxyurea | 1 | 2013 | 223 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 2 | 2009 | 887 | 0.100 |
Why?
|
| Retinoblastoma Protein | 2 | 2004 | 342 | 0.100 |
Why?
|
| Cell Cycle Proteins | 3 | 2007 | 2125 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 4 | 2007 | 3245 | 0.100 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2011 | 157 | 0.090 |
Why?
|
| Interferon-gamma | 1 | 2015 | 1184 | 0.090 |
Why?
|
| Cyclooxygenase 2 | 2 | 2013 | 496 | 0.090 |
Why?
|
| Rats | 6 | 2006 | 6635 | 0.090 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2011 | 271 | 0.090 |
Why?
|
| PPAR gamma | 1 | 2011 | 231 | 0.090 |
Why?
|
| Down-Regulation | 4 | 2011 | 2109 | 0.090 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1994 | 472 | 0.090 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2008 | 1233 | 0.090 |
Why?
|
| Placebos | 1 | 2011 | 446 | 0.090 |
Why?
|
| United States | 4 | 2014 | 15981 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2012 | 5105 | 0.090 |
Why?
|
| Thiophenes | 2 | 2011 | 149 | 0.090 |
Why?
|
| Response Elements | 2 | 2007 | 200 | 0.090 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2009 | 123 | 0.080 |
Why?
|
| T-Lymphocytes | 5 | 1986 | 3928 | 0.080 |
Why?
|
| Protein Phosphatase 2C | 1 | 2009 | 86 | 0.080 |
Why?
|
| Research Design | 2 | 2008 | 1568 | 0.080 |
Why?
|
| Epiregulin | 1 | 2009 | 14 | 0.080 |
Why?
|
| Double-Blind Method | 3 | 2014 | 2618 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 2 | 2009 | 1214 | 0.080 |
Why?
|
| Luciferases | 3 | 2006 | 462 | 0.080 |
Why?
|
| DNA-Binding Proteins | 6 | 2004 | 5042 | 0.080 |
Why?
|
| Flow Cytometry | 3 | 2006 | 3083 | 0.080 |
Why?
|
| Growth Substances | 2 | 2002 | 329 | 0.080 |
Why?
|
| Eicosanoids | 1 | 2008 | 30 | 0.080 |
Why?
|
| Receptors, Androgen | 1 | 2014 | 922 | 0.080 |
Why?
|
| Cyclin D | 1 | 2008 | 40 | 0.080 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 1571 | 0.080 |
Why?
|
| Apoptosis | 5 | 2006 | 7847 | 0.080 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2009 | 223 | 0.080 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 1985 | 191 | 0.080 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2009 | 178 | 0.080 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 499 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 2 | 2012 | 1469 | 0.080 |
Why?
|
| Clone Cells | 3 | 2007 | 592 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2001 | 1666 | 0.070 |
Why?
|
| Age Factors | 2 | 2008 | 5492 | 0.070 |
Why?
|
| Transcription Factor DP1 | 1 | 2007 | 59 | 0.070 |
Why?
|
| E2F2 Transcription Factor | 1 | 2007 | 27 | 0.070 |
Why?
|
| beta Catenin | 2 | 2009 | 690 | 0.070 |
Why?
|
| E2F4 Transcription Factor | 1 | 2007 | 30 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2014 | 2093 | 0.070 |
Why?
|
| Internet | 1 | 2012 | 698 | 0.070 |
Why?
|
| Wnt Proteins | 1 | 2009 | 391 | 0.070 |
Why?
|
| Substrate Specificity | 1 | 2008 | 582 | 0.070 |
Why?
|
| Drug Industry | 1 | 2007 | 89 | 0.070 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 1986 | 1734 | 0.070 |
Why?
|
| Middle Aged | 11 | 2014 | 90016 | 0.070 |
Why?
|
| Trans-Activators | 2 | 2004 | 1655 | 0.070 |
Why?
|
| Time Factors | 4 | 2007 | 13110 | 0.070 |
Why?
|
| Protein Binding | 3 | 2007 | 3536 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2009 | 1045 | 0.070 |
Why?
|
| Research Support as Topic | 1 | 2007 | 120 | 0.070 |
Why?
|
| Adult | 11 | 2013 | 81545 | 0.070 |
Why?
|
| Gene Silencing | 1 | 2009 | 834 | 0.070 |
Why?
|
| Publishing | 1 | 2008 | 196 | 0.070 |
Why?
|
| Leuprolide | 1 | 2006 | 67 | 0.070 |
Why?
|
| Transplantation, Heterologous | 2 | 2006 | 1089 | 0.070 |
Why?
|
| Receptors, Calcitriol | 1 | 2007 | 150 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2008 | 573 | 0.070 |
Why?
|
| Carcinoma, Lobular | 1 | 2010 | 617 | 0.070 |
Why?
|
| Zinc Fingers | 1 | 2007 | 222 | 0.070 |
Why?
|
| Apigenin | 1 | 2006 | 12 | 0.070 |
Why?
|
| Radiation Chimera | 1 | 1986 | 34 | 0.070 |
Why?
|
| E2F1 Transcription Factor | 1 | 2007 | 202 | 0.070 |
Why?
|
| Proteome | 1 | 2010 | 572 | 0.070 |
Why?
|
| Inhibitor of Differentiation Protein 1 | 1 | 2006 | 16 | 0.070 |
Why?
|
| Risk Factors | 7 | 2014 | 17820 | 0.070 |
Why?
|
| Aspirin | 1 | 2009 | 390 | 0.070 |
Why?
|
| Drug Costs | 1 | 2007 | 141 | 0.070 |
Why?
|
| Genistein | 1 | 2006 | 76 | 0.070 |
Why?
|
| RNA | 2 | 2004 | 1067 | 0.070 |
Why?
|
| Molecular Sequence Data | 6 | 2011 | 6784 | 0.070 |
Why?
|
| Vinblastine | 1 | 2006 | 462 | 0.060 |
Why?
|
| Enzyme Activation | 2 | 2007 | 1834 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2013 | 2423 | 0.060 |
Why?
|
| Ovariectomy | 1 | 2006 | 372 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2007 | 486 | 0.060 |
Why?
|
| Lung Neoplasms | 6 | 2009 | 11761 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 474 | 0.060 |
Why?
|
| Piperidines | 2 | 2011 | 1089 | 0.060 |
Why?
|
| Neoplasm Transplantation | 2 | 2007 | 1567 | 0.060 |
Why?
|
| Germ-Line Mutation | 1 | 2010 | 1069 | 0.060 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2007 | 237 | 0.060 |
Why?
|
| Biomarkers | 5 | 2013 | 5105 | 0.060 |
Why?
|
| Patient Selection | 1 | 2012 | 2042 | 0.060 |
Why?
|
| Dietary Supplements | 1 | 2008 | 566 | 0.060 |
Why?
|
| Cellular Senescence | 1 | 2006 | 390 | 0.060 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2008 | 631 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2006 | 2366 | 0.060 |
Why?
|
| Mitosis | 1 | 2006 | 690 | 0.060 |
Why?
|
| Blood | 1 | 2004 | 171 | 0.060 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2009 | 693 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 3 | 2007 | 4067 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 2 | 2004 | 1502 | 0.060 |
Why?
|
| Sp1 Transcription Factor | 1 | 2004 | 193 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2007 | 906 | 0.060 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2004 | 632 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 1725 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2011 | 848 | 0.060 |
Why?
|
| Imidazoles | 1 | 2009 | 1059 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2002 | 540 | 0.060 |
Why?
|
| Genes, ras | 3 | 1996 | 680 | 0.050 |
Why?
|
| Multigene Family | 1 | 2004 | 459 | 0.050 |
Why?
|
| Genes, MHC Class II | 1 | 1983 | 68 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2004 | 565 | 0.050 |
Why?
|
| Culture Media, Serum-Free | 1 | 2002 | 81 | 0.050 |
Why?
|
| Imatinib Mesylate | 1 | 2007 | 1691 | 0.050 |
Why?
|
| Mammography | 1 | 2009 | 1045 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 3653 | 0.050 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 1135 | 0.050 |
Why?
|
| Genetic Counseling | 1 | 2005 | 405 | 0.050 |
Why?
|
| Pyridines | 1 | 2009 | 1311 | 0.050 |
Why?
|
| Cells, Cultured | 4 | 2011 | 5781 | 0.050 |
Why?
|
| Protein Kinases | 2 | 1998 | 917 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2001 | 78 | 0.050 |
Why?
|
| DNA | 3 | 2001 | 3072 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2009 | 7809 | 0.050 |
Why?
|
| Dimerization | 2 | 2005 | 318 | 0.050 |
Why?
|
| Benzamides | 1 | 2007 | 1883 | 0.050 |
Why?
|
| Ovarian Neoplasms | 2 | 2015 | 4774 | 0.050 |
Why?
|
| Aged | 6 | 2014 | 73160 | 0.050 |
Why?
|
| Ligands | 4 | 2009 | 1061 | 0.050 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2001 | 451 | 0.050 |
Why?
|
| Benzoates | 1 | 2002 | 130 | 0.050 |
Why?
|
| Base Sequence | 4 | 1996 | 5495 | 0.050 |
Why?
|
| Microfilament Proteins | 1 | 2003 | 496 | 0.050 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2014 | 360 | 0.050 |
Why?
|
| Cell Movement | 2 | 2006 | 2500 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2006 | 1229 | 0.040 |
Why?
|
| Sequence Deletion | 2 | 1994 | 909 | 0.040 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2000 | 154 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2002 | 388 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 1986 | 1773 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2008 | 1462 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2006 | 1524 | 0.040 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 541 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2012 | 2159 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2001 | 505 | 0.040 |
Why?
|
| Mastectomy, Segmental | 1 | 2005 | 1047 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2013 | 1322 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2006 | 1836 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2009 | 5836 | 0.040 |
Why?
|
| Cell Line, Transformed | 1 | 1999 | 431 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2006 | 1599 | 0.040 |
Why?
|
| Piperazines | 1 | 2007 | 2153 | 0.040 |
Why?
|
| Lymph Nodes | 2 | 2006 | 3067 | 0.040 |
Why?
|
| Europe | 1 | 1999 | 647 | 0.040 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 1997 | 95 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2011 | 1119 | 0.040 |
Why?
|
| Rhabdomyosarcoma | 1 | 2001 | 342 | 0.040 |
Why?
|
| Survival Rate | 3 | 2006 | 12516 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2004 | 1583 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2015 | 5233 | 0.040 |
Why?
|
| Software | 1 | 2004 | 1361 | 0.040 |
Why?
|
| Lymphoma | 1 | 1986 | 1514 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 5990 | 0.040 |
Why?
|
| Neoplasm Staging | 3 | 2012 | 13976 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2005 | 3972 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2005 | 33819 | 0.040 |
Why?
|
| Algorithms | 1 | 2008 | 3908 | 0.030 |
Why?
|
| Transformation, Genetic | 1 | 1996 | 70 | 0.030 |
Why?
|
| Rats, Inbred F344 | 2 | 1994 | 238 | 0.030 |
Why?
|
| Stimulation, Chemical | 1 | 1996 | 112 | 0.030 |
Why?
|
| DNA Mutational Analysis | 2 | 2010 | 2350 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2001 | 1742 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 1997 | 831 | 0.030 |
Why?
|
| Epithelium | 1 | 1997 | 805 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2012 | 4787 | 0.030 |
Why?
|
| Estrogen Receptor Antagonists | 1 | 2014 | 9 | 0.030 |
Why?
|
| Androstenedione | 1 | 2014 | 19 | 0.030 |
Why?
|
| Diet | 1 | 2003 | 1485 | 0.030 |
Why?
|
| Histones | 1 | 2002 | 1510 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2007 | 3666 | 0.030 |
Why?
|
| Kinetics | 1 | 1997 | 2246 | 0.030 |
Why?
|
| Leucine Zippers | 1 | 1994 | 41 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 1996 | 1011 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2000 | 1158 | 0.030 |
Why?
|
| Carcinogens | 2 | 1993 | 391 | 0.030 |
Why?
|
| Teratocarcinoma | 1 | 1993 | 24 | 0.030 |
Why?
|
| Mastectomy | 1 | 2000 | 1547 | 0.030 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2013 | 17 | 0.030 |
Why?
|
| Antigens, Surface | 2 | 1985 | 313 | 0.030 |
Why?
|
| Genes, Suppressor | 1 | 1993 | 24 | 0.030 |
Why?
|
| Receptors, Progesterone | 2 | 2012 | 1645 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 5185 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2004 | 3459 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 1993 | 339 | 0.030 |
Why?
|
| Fungal Proteins | 1 | 1994 | 271 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2014 | 553 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2014 | 593 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2013 | 257 | 0.030 |
Why?
|
| Bone Demineralization, Pathologic | 1 | 2011 | 5 | 0.030 |
Why?
|
| Prognosis | 4 | 2013 | 22456 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2013 | 222 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2013 | 360 | 0.020 |
Why?
|
| Norpregnenes | 1 | 2011 | 5 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 1993 | 419 | 0.020 |
Why?
|
| Proto-Oncogenes | 1 | 1992 | 208 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2011 | 162 | 0.020 |
Why?
|
| Cell Transformation, Viral | 1 | 1991 | 174 | 0.020 |
Why?
|
| Up-Regulation | 2 | 2009 | 2465 | 0.020 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2011 | 78 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 1997 | 3492 | 0.020 |
Why?
|
| Obesity | 1 | 2004 | 2940 | 0.020 |
Why?
|
| Adenocarcinoma | 2 | 2006 | 7936 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2011 | 815 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2011 | 4641 | 0.020 |
Why?
|
| Fenretinide | 1 | 2011 | 100 | 0.020 |
Why?
|
| Pyrrolidines | 1 | 2011 | 114 | 0.020 |
Why?
|
| Premenopause | 1 | 2011 | 139 | 0.020 |
Why?
|
| Protein Stability | 1 | 2011 | 374 | 0.020 |
Why?
|
| Expert Testimony | 1 | 2011 | 84 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2013 | 390 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1993 | 1744 | 0.020 |
Why?
|
| Androstadienes | 1 | 2011 | 172 | 0.020 |
Why?
|
| Carcinoma, Small Cell | 1 | 1993 | 427 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2005 | 15247 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2011 | 658 | 0.020 |
Why?
|
| Glutathione Transferase | 2 | 2001 | 368 | 0.020 |
Why?
|
| Genetic Markers | 1 | 1992 | 1015 | 0.020 |
Why?
|
| Diphosphonates | 1 | 2011 | 264 | 0.020 |
Why?
|
| Digestive System Neoplasms | 1 | 2009 | 77 | 0.020 |
Why?
|
| Bone Density | 1 | 2011 | 470 | 0.020 |
Why?
|
| Pyridones | 1 | 2011 | 361 | 0.020 |
Why?
|
| Authorship | 1 | 2008 | 47 | 0.020 |
Why?
|
| Age of Onset | 1 | 2010 | 824 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2005 | 3073 | 0.020 |
Why?
|
| Efficiency | 1 | 2008 | 93 | 0.020 |
Why?
|
| Drug Synergism | 2 | 2006 | 1369 | 0.020 |
Why?
|
| Benzimidazoles | 1 | 2011 | 441 | 0.020 |
Why?
|
| Lipids | 1 | 2011 | 659 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 1065 | 0.020 |
Why?
|
| Metformin | 1 | 2011 | 395 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2008 | 274 | 0.020 |
Why?
|
| Tubulin Modulators | 1 | 2006 | 65 | 0.020 |
Why?
|
| Physician's Role | 1 | 2008 | 231 | 0.020 |
Why?
|
| Neoplasms, Ductal, Lobular, and Medullary | 1 | 2006 | 4 | 0.020 |
Why?
|
| Family | 1 | 2010 | 762 | 0.020 |
Why?
|
| G2 Phase | 1 | 2006 | 218 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2006 | 145 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2009 | 704 | 0.020 |
Why?
|
| DNA, Antisense | 1 | 2005 | 44 | 0.020 |
Why?
|
| Quality of Life | 1 | 2000 | 4731 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 1986 | 254 | 0.020 |
Why?
|
| Neuraminidase | 1 | 1985 | 48 | 0.020 |
Why?
|
| Peritoneal Cavity | 1 | 1985 | 58 | 0.020 |
Why?
|
| Neuregulin-1 | 1 | 2005 | 89 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2010 | 1435 | 0.020 |
Why?
|
| Species Specificity | 1 | 2007 | 809 | 0.020 |
Why?
|
| Microcirculation | 1 | 2006 | 194 | 0.020 |
Why?
|
| Estrogen Receptor beta | 1 | 2006 | 168 | 0.020 |
Why?
|
| Genetic Engineering | 1 | 2007 | 299 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1985 | 615 | 0.020 |
Why?
|
| Gamma Rays | 1 | 1986 | 241 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2006 | 916 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1985 | 570 | 0.020 |
Why?
|
| Risk | 1 | 2009 | 1914 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2009 | 671 | 0.020 |
Why?
|
| Integrins | 1 | 2006 | 277 | 0.020 |
Why?
|
| Thymus Gland | 1 | 1986 | 310 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 6027 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1985 | 623 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 1 | 1985 | 289 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2011 | 1467 | 0.010 |
Why?
|
| Health Behavior | 1 | 2008 | 597 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2007 | 1070 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 2560 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 1986 | 425 | 0.010 |
Why?
|
| Genetic Testing | 1 | 1992 | 1668 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 2007 | 791 | 0.010 |
Why?
|
| Genetic Vectors | 2 | 2001 | 1884 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1983 | 97 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 1985 | 593 | 0.010 |
Why?
|
| DNA, Recombinant | 1 | 1983 | 160 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2011 | 7216 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2002 | 44 | 0.010 |
Why?
|
| Liver | 1 | 2012 | 3124 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 1983 | 137 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2008 | 843 | 0.010 |
Why?
|
| Antigens, Neoplasm | 2 | 1985 | 1589 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2006 | 896 | 0.010 |
Why?
|
| Glycoproteins | 1 | 1985 | 796 | 0.010 |
Why?
|
| Logistic Models | 1 | 2009 | 3437 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 1983 | 664 | 0.010 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2002 | 162 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 6248 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2002 | 279 | 0.010 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2001 | 181 | 0.010 |
Why?
|
| Keratins | 1 | 2002 | 352 | 0.010 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2001 | 233 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 2000 | 139 | 0.010 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2001 | 167 | 0.010 |
Why?
|
| Disease Progression | 1 | 2012 | 6890 | 0.010 |
Why?
|
| COS Cells | 1 | 2001 | 422 | 0.010 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2000 | 72 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2002 | 300 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1983 | 683 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1983 | 1460 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 1293 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 4327 | 0.010 |
Why?
|
| Lipid Peroxidation | 1 | 2000 | 161 | 0.010 |
Why?
|
| Gene Library | 1 | 2001 | 357 | 0.010 |
Why?
|
| Superoxide Dismutase | 1 | 2000 | 270 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2001 | 956 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1985 | 1424 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2001 | 948 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 1091 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 10249 | 0.010 |
Why?
|
| Plasmids | 1 | 2001 | 952 | 0.010 |
Why?
|
| Phenotype | 2 | 2000 | 6464 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1998 | 120 | 0.010 |
Why?
|
| Vimentin | 1 | 1999 | 265 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 1998 | 178 | 0.010 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 1998 | 146 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1986 | 2434 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1998 | 257 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1997 | 736 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2001 | 774 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1996 | 387 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2002 | 1268 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1993 | 5517 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2007 | 3349 | 0.010 |
Why?
|
| Temperature | 1 | 1996 | 541 | 0.010 |
Why?
|
| Drug Therapy | 1 | 1995 | 206 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2009 | 3657 | 0.010 |
Why?
|
| Male | 2 | 2014 | 128412 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 22054 | 0.010 |
Why?
|
| Gastrin-Releasing Peptide | 1 | 1993 | 6 | 0.010 |
Why?
|
| Gastrins | 1 | 1993 | 55 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1991 | 362 | 0.010 |
Why?
|
| Adolescent | 1 | 2012 | 32556 | 0.010 |
Why?
|
| Granulocytes | 1 | 1991 | 243 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1983 | 4509 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1996 | 1669 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 30941 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2002 | 3532 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1993 | 1730 | 0.000 |
Why?
|
| Hematopoiesis | 1 | 1991 | 606 | 0.000 |
Why?
|
| Peptides | 1 | 1993 | 1529 | 0.000 |
Why?
|
| Adenoma | 1 | 1992 | 741 | 0.000 |
Why?
|
| Histocompatibility Antigens | 1 | 1985 | 79 | 0.000 |
Why?
|
| Cross Reactions | 1 | 1985 | 269 | 0.000 |
Why?
|
| Macrophages | 1 | 1991 | 1368 | 0.000 |
Why?
|
| Epitopes | 1 | 1985 | 711 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 2006 | 39688 | 0.000 |
Why?
|
| Killer Cells, Natural | 1 | 1986 | 958 | 0.000 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1992 | 5567 | 0.000 |
Why?
|